Photocure (OL:PHO) — Market Cap & Net Worth
Market Cap & Net Worth: Photocure (PHO)
Photocure (OL:PHO) has a market capitalization of $144.74 Million (Nkr1.38 Billion) as of September 17, 2026. Listed on the OL stock exchange, this Norway-based company holds position #17887 globally and #154 in its home market, demonstrating a -4.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Photocure's stock price Nkr51.10 by its total outstanding shares 26916610 (26.92 Million). Also see PHO asset base for a full breakdown of the balance sheet.
Photocure Market Cap History: 2015 to 2026
Photocure's market capitalization history from 2015 to 2026. Data shows growth from $118.68 Million to $144.74 Million (2.39% CAGR). Also see PHO operating cash flow for how efficiently the company converts equity into cash flow.
Photocure Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Photocure's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Photocure (PHO) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.38x
Photocure's market cap is 0.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $118.96 Million | $143.63 Million | $35.31 Million | 0.83x | 3.37x |
| 2017 | $77.32 Million | $150.91 Million | -$34.70 Million | 0.51x | N/A |
| 2018 | $135.96 Million | $181.51 Million | -$36.71 Million | 0.75x | N/A |
| 2019 | $253.50 Million | $281.56 Million | $31.83 Million | 0.90x | 7.96x |
| 2020 | $301.93 Million | $256.48 Million | -$22.40 Million | 1.18x | N/A |
| 2021 | $290.89 Million | $360.54 Million | -$30.90 Million | 0.81x | N/A |
| 2022 | $302.50 Million | $393.13 Million | -$71.86 Million | 0.77x | N/A |
| 2023 | $190.90 Million | $500.66 Million | $979.00K | 0.38x | 195.00x |
| 2024 | $175.61 Million | $525.39 Million | -$3.34 Million | 0.33x | N/A |
| 2025 | $202.23 Million | $532.58 Million | -$1.52 Million | 0.38x | N/A |
Competitor Companies of PHO by Market Capitalization
Companies near Photocure in the global market cap rankings as of September 17, 2026. Review how tangible is Photocure's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Photocure by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Photocure Historical Marketcap From 2015 to 2026
Between 2015 and today, Photocure's market cap moved from $118.68 Million to $ 144.74 Million, with a yearly change of 2.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr144.74 Million | -28.43% |
| 2025 | Nkr202.23 Million | +15.16% |
| 2024 | Nkr175.61 Million | -8.01% |
| 2023 | Nkr190.90 Million | -36.89% |
| 2022 | Nkr302.50 Million | +3.99% |
| 2021 | Nkr290.89 Million | -3.66% |
| 2020 | Nkr301.93 Million | +19.11% |
| 2019 | Nkr253.50 Million | +86.46% |
| 2018 | Nkr135.96 Million | +75.82% |
| 2017 | Nkr77.32 Million | -35.00% |
| 2016 | Nkr118.96 Million | +0.24% |
| 2015 | Nkr118.68 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Photocure was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $144.74 Million USD |
| MoneyControl | $144.74 Million USD |
| MarketWatch | $144.74 Million USD |
| marketcap.company | $144.74 Million USD |
| Reuters | $144.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination pro… Read more